A survey from Gallup found the percentage of Americans taking GLP-1s jumped from 5.8 percent in early 2024 to 12.4 percent in mid-2025more than doubling in less than two years
Risk factors include age, vegan diets, certain diseases, and some medicines
& Landau, N
Clinical trial data showed participants experiencing severe, persistent vomiting lasting weeks (a hallmark symptom of gastroparesis), yet this information was characterized as temporary gastrointestinal adverse events in public communications
Why Consistency Matters for Weight Loss and Appetite Control Semaglutide's therapeutic benefit depends on stable, accumulating levels in your system over weeks and months
Labarrere, [email protected] This article was submitted to Nutritional Immunology, a section of the journal Frontiers in Nutrition Disclaimer All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers